Innovations, Biomarkers, and Challenges in Cancer Immunotherapy
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 10 May 2026 | Viewed by 16
Special Issue Editors
Interests: next-generation cellular therapies; exosome-based immunotherapy; combination therapies; translational oncology in immunotherapy; biomarkers
Interests: bone marrow transplantation; stem cell transplantation; immunological mechanism of Graft versus Host Disease (GvHD); Graft versus Leukemia (GvL) relapse/remission; immune cell reconstitution; post hematopoietic stem cell transplantation (HSCT); cellular therapy (CT); transplant immunology; immune regulatory ; modulatory mechanisms in allogenic HSCT; immune tolerance induction pathways; understanding HLA loss and its implication in managing disease relapse; post HSCT Cell-based therapeutics; clinical cGMP manufacturing
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has transformed the treatment landscape for many malignancies, offering unprecedented clinical benefits; however, despite these advances, challenges such as limited response rates, immune evasion, therapy-related toxicity, and lack of predictive biomarkers remain significant obstacles. In parallel, innovative approaches including CAR-NK cells, CAR-T cells, exosome-based therapeutics, and combination strategies are rapidly emerging, showing promise in preclinical and early clinical studies. This Special Issue, “Innovations, Biomarkers, and Challenges in Cancer Immunotherapy”, aims to provide a platform for reporting and discussing cutting-edge research that addresses these challenges and accelerates the translation of novel immunotherapies into clinical practice. We welcome submissions on next-generation cellular therapies, combination strategies (e.g., CAR-NK or CAR-T cells with checkpoint inhibitors, T-cell engagers with chemotherapy, or exosomes with immune stimulators), exosome-based interventions, biomarkers for predicting or monitoring therapy response, and studies exploring the tumor microenvironment or mechanisms of immune resistance. We invite authors worldwide to contribute high-quality manuscripts that highlight innovations, tackle core clinical problems, and help shape the future of cancer immunotherapy.
Dr. Mohammad Mousaei Ghasroldasht
Dr. Mahzad Akbarpour
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- next-generation cellular therapies
- CAR-NK cell therapy
- CAR-T cell therapy
- combination strategies
- exosomes
- T-cell engagers
- oncolytic viruses
- cancer immunotherapy
- biomarkers for therapy response
- translational immunotherapy
- tumor microenvironment modulation
- immune evasion mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
